Get started
Author

Catherine Eagle

Observed name: Catherine J Eagle
OpenAlex ID: A5063198530
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling
2015 · Bettina C Urban, Tracey J Collard, et al. · Gut · 53
PDF
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2022 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research Communications · 40
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition
2022 · Dustin J. Flanagan, Simon A. Woodcock, et al. · Pharmacology & Therapeutics · 36
PDF
Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer
2019 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research · 11
Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
2018 · Inder Bhamra, Richard Armer, et al. · Cancer Research · 9
Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer
2019 · Simon Woodcock, Inder Bhamra, et al. · Cancer Research · 5
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors
2022 · Natalie Cook, Sarah Blagden, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 998: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer
2021 · Caroline Phillips, Simon Woodcock, et al. · Cancer Research · 2
Abstract 944: Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer models
2024 · Simon A. Woodcock, Dorottya Keppel, et al. · Cancer Research · 1
Data from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Supplementary Figures 1-7, Table 1 from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancer
2023 · Simon A. Woodcock, Dorottya Keppel, et al. · Cancer Research
Data from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer
2019 · Caroline Phillips, Inder Bhamra, et al. · Immunology
Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer
2019 · Simon Woodcock, Inder Bhamra, et al. · Experimental and Molecular Therapeutics
Abstract 5581: Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors
2017 · Thomas Pesnot, Sachin Mahale, et al. · Cancer Research
Works count: 16
Citation count: 159
H-index: 5
I10-index: 4
Year
Topic
Type